Brinton Seashore-Ludlow

Key publications

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.
Cancer Discov 5 (11):1210-1223. doi:10.1158/2159-8290.CD-15-0235
Seashore-Ludlow B, Rees MG, Cheah JH, Cokol M, Price EV, Coletti ME, Jones V, Bodycombe NE, Soule CK, Gould J, Alexander B, Li A, Montgomery P, Wawer MJ, Kuru N, Kotz JD, Hon CS, Munoz B, Liefeld T, Dančík V, Bittker JA, Palmer M, Bradner JE, Shamji AF, Clemons PA, Schreiber SL (2015)

Correlating chemical sensitivity and basal gene expression reveals mechanism of action.
Nat Chem Biol 12 (2):109-116. doi:10.1038/nchembio.1986
Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, Soule CK, Alexander B, Li A, Montgomery P, Kotz JD, Hon CS, Munoz B, Liefeld T, Dančík V, Haber DA, Clish CB, Bittker JA, Palmer M, Wagner BK, Clemons PA, Shamji AF, Schreiber SL (2016)

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.
Nature 547 (7664):453-457. doi:10.1038/nature23007
Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, Chen S, Boskovic ZV, Javaid S, Huang C, Wu X, Tseng YY, Roider EM, Gao D, Cleary JM, Wolpin BM, Mesirov JP, Haber DA, Engelman JA, Boehm JS, Kotz JD, Hon CS, Chen Y, Hahn WC, Levesque MP, Doench JG, Berens ME, Shamji AF, Clemons PA, Stockwell BR, Schreiber SL (2017)

Quantitative Interpretation of Intracellular Drug Binding and Kinetics Using the Cellular Thermal Shift Assay.
Biochemistry 57 (48):6715-6725. doi:10.1021/acs.biochem.8b010
Axelsson H, Almqvist H, Otrocka M, Vallin M, Lundqvist S, Hansson P, Karlsson U, Lundbäck T, Seashore-Ludlow B (2018) In Situ Target Engagement Studies in Adherent Cells. ACS Chem Biol 13 (4):942-950. doi:10.1021/acschembio.7b01079
Seashore-Ludlow B, Axelsson H, Almqvist H, Dahlgren B, Jonsson M, Lundbäck T (2018)

PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.
Cancers (Basel) 13 (14). doi:10.3390/cancers13143604
Ninou AH, Lehto J, Chioureas D, Stigsdotter H, Schelzig K, Åkerlund E, Gudoityte G, Joneborg U, Carlson J, Jonkers J, Seashore-Ludlow B, Gustafsson NMS (2021)

Brinton Seashore-Ludlow

Our ultimate goal is to promote the move away from one-size-fits-all therapies to improve patient outcome through treatment stratification and tailoring. Despite advances in precision medicine diagnostics, there are still major opportunities to improve individualized patient care throughout the entire health care value chain, spanning from preclinical studies in drug discovery through to the design of precision diagnostics.

Research in my team focuses on challenges central to these fields, namely developing technologies and disease models that enable direct measurement of patient response to treatment ex vivo and investigation of the molecular determinants of drug response. Such methods and model systems are critical to improve the study of disease biology, identify and validate new drug targets, correctly prioritize drug candidates for clinical trials, uncover potential biomarkers for future patient stratification and have even recently been used to successfully as diagnostics to match patients to effective treatments.

Our translational research group and surrounding team of clinicians and experts has two major themes as described below united by the main goal of investigating drug response and biomarkers in primary patient cells and other near-patient models of disease.

Group Members

  • Greta Gudoityte
  • Mariam Haffa
  • Osheen Sharma
  • Emma Åkerlund

Last updated: 2022-11-30

Content Responsible: David Gotthold(